Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan

Review

SHALENDER BHASIN,* ATAM B. SINGH,* RICKY PHONG MAC,* BALLENTINE CARTER,† MARTIN I. LEE,* AND GLENN R. CUNNINGHAM‡

*From the *Division of Endocrinology, Metabolism, and Molecular Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, California; †Division of Urology, Johns Hopkins University, School of Medicine, Baltimore, Maryland; and ‡Division of Endocrinology, Baylor College of Medicine, Houston, Texas.*

Growing Use of Androgenic Products

The powerful demographic trend toward aging of populations in most countries has appropriately focused attention on the health problems of older men. Although there is agreement that serum total, bioavailable, and free testosterone concentrations decline with advancing age (Haffner et al, 1996; Kaufman and Vermeulen 1997; Morley et al, 1997; Zmuda et al, 1997; Smith et al, 2000; Harman et al, 2001), there is considerable uncertainty about the benefits and risks of testosterone replacement in older men with low testosterone concentrations (Bhasin and Buckwalter 2001; Matsumoto 2002). Initial randomized, placebo-controlled studies (Tenover 1992, 1998; Morley et al, 1993; Sih et al, 1997; Snyder et al, 1999a,b; Urban 1999; Kenny et al, 2001) have established the feasibility of testosterone replacement in older men for up to 3 years, and demonstrated that testosterone replacement increases fat-free mass, sense of well-being, and bone mineral density, and decreases fat mass in older men with low or low-normal testosterone concentrations. However, these initial studies (Tenover 1992, 1998; Morley et al, 1993; Sih et al, 1997; Snyder et al, 1999a,b; Urban 1999; Kenny et al, 2001) were neither designed to determine the effects of testosterone supplementation on health outcomes such as fracture rates, falls, physical function, dis-

Correspondence to: Dr Shalender Bhasin, Division of Endocrinology, Metabolism, and Molecular Medicine, UCLA–Charles R. Drew University of Medicine and Science, 1731 East 120th Street, Los Angeles, CA 90059 (e-mail: sbhasin@ucla.edu).

ability, neurocognitive ability, and progression to dementia, nor powered to evaluate the effects of androgen administration on prostate and cardiovascular event rates. Long-term studies of 1 to 3 years in duration (Sih et al, 1997; Tenover 1998; Snyder et al, 1999a,b; Kenny et al, 2001) have generally reported a greater increase in hematocrit with testosterone administration than that associated with placebo administration. A few older men will develop hematocrits >55% during testosterone administration; increases in hematocrit to these high levels would increase blood viscosity, decrease blood flow rates, and might increase the risk of stroke. Androgen replacement may also worsen or induce sleep apnea, and cause edema, especially in older men with pre-existing heart disease.

In the context of this uncertainty about the long-term risks of testosterone supplementation in older men, it is notable that testosterone prescription sales have increased 1700% in the last 9 years, and have grown 460% just in the last 3 years. Testosterone sales that had been stagnant at about $18 million until 1988 are projected to reach $400 million before the end of 2002 (IMS sales data, Philadelphia, Pa; BMC Corporation sales data, Minneapolis, Minn). Whereas the greatest growth in testosterone sales appears to be in men with hypogonadism and younger than 65 years of age, testosterone use is also growing in older men. A growing interest in testosterone use is reflected in greater media and public attention that this topic has received.

Although prostate event rates have not been significantly different between placebo- and testosterone-treated men in the previously published studies of testosterone replacement in older men (Sih et al, 1997; Tenover 1998; Snyder et al, 1999a,b), it is important to recognize that these studies did not have sufficient power to detect significant differences in prostate event rates between the 2 groups. It has been estimated that in order to detect a 30% difference in prostate cancer incidence rates between the placebo- and testosterone-treated groups, it would require randomization of approximately 6000 older men with low testosterone levels to the placebo and testosterone groups and treatment for an average of 5 years. Because such a randomized clinical trial would likely include relatively healthy older men with unequivocally low testosterone levels who do not have prostate cancer or prostate-specific

antigen (PSA) levels >4 ng/mL, this would require screening a significantly larger number of older men in order to enroll 6000 eligible men. Accrual of sufficient numbers of men in such a clinical trial would be a challenging task. At this time, no study of this size has been funded; therefore, we will not know for several years whether testosterone replacement increases the incidence of clinically overt prostate cancer.

Because the baseline prevalence of benign as well as malignant prostatic disorders is high (Berry et al, 1984; Carter et al, 1990; Sakr et al, 1994; Coley et al, 1995; Hsing et al, 2000; Jemal et al, 2002) in older men and the risks of prostate problems during testosterone administration remain undefined, there is understandable anxiety among health care providers who are facing increasing pressure from patients to consider hormone replacement. Therefore, the objectives of this commentary are to review the available data on the effects of testosterone replacement on the risk of prostatic disease in older men, and to present some recommendations for prostate monitoring during androgen administration in older men.

This review should not be construed as our endorsement of testosterone replacement in older men with low testosterone concentrations. Our position is that at present, insufficient data exist to warrant a general recommendation for testosterone replacement of all older men with low testosterone concentrations, but that in some patients with unequivocally low testosterone levels and clinical and laboratory findings that can be attributed to androgen deficiency, individualized testosterone replacement might be justified after appropriate discussion of the benefits and risks with the patient, and institution of a standardized monitoring plan to maximize patient safety and minimize risk.

Issues Associated With Prostate Risks and Monitoring in Older Men

Most but not all authorities believe that testosterone does not cause prostate cancer. Also, there is no consistent relationship between endogenous serum testosterone levels and the risk of prostate cancer. However, there are a number of areas of concern.

1) Prostate cancer is a common, androgen–dependent tumor, and androgen administration promotes tumor growth in patients with metastatic prostate cancer (Fowler and Whitmore 1981; Manni et al, 1988; Santen et al, 1990). Therefore, testosterone administration is absolutely contraindicated in men with a clinical prostate cancer.

2) PSA levels increase with age in men who do not have clinical prostate cancer (Oesterling et al, 1993), and levels are higher in blacks than in whites (Morgan et al, 1996).

3) Some men with PSA <4.0 ng/mL will have or will develop clinical prostate cancer. The risk of developing a clinical prostate cancer is related to the baseline PSA value (Gann et al, 1995; Fang et al, 2001).

4) Many older men have occult, microscopic foci of cancer in their prostates (Guileyardo et al, 1980; Carter et al, 1990; Sakr et al, 1994). We do not know whether testosterone administration will make these subclinical foci of cancer grow and become clinically overt.

5) Older men with low testosterone levels may have occult or clinical prostate cancer (Morgentaler, 1996; Schatzl et al, 2001). Because PSA levels may be lower in men with androgen deficiency than in men with eugonadism, PSA levels in men with low testosterone levels may not accurately reflect the presence of prostate cancer.

6) Serum PSA levels may be lower in men with testosterone deficiency and are restored to levels seen in age-matched controls following testosterone replacement (Sasagawa, 1990; Behre, 1994; Cooper et al, 1996; Meikle et al, 1997; Svetec et al, 1997). Therefore, in men receiving testosterone replacement, it is important to determine whether the increments in PSA levels are greater than what is expected after testosterone administration in men without prostate cancer. Increased PSA levels can be caused by prostatitis, assay variability, differences between PSA assays, biological variability, testosterone replacement, benign prostatic hyperplasia (BPH), as well as prostate cancer. When PSA levels in men with androgen deficiency and a testosterone replacement regimen show a change from baseline or from a previously measured value, the clinician must consider each of these factors before suggesting that the patient undergo prostate biopsies.

7) More intensive PSA screening and follow-up of men receiving testosterone replacement might lead to greater numbers of prostate biopsies and detection of subclinical prostate cancers that would have otherwise remained undetected. Therefore, it is important to set criteria for monitoring PSA changes during testosterone supplementation. Criteria that use very low thresholds for performing prostate biopsy relative to test-retest variability will likely result in an excessive number of biopsies with their associated costs, psychological trauma, and morbidity. On the other hand, criteria that use unreasonably high thresholds for performing prostate biopsies may fail to detect clinical prostate cancers at an early stage.

Testosterone and Prostate Cancer Risk

Many Clinically Overt Prostate Cancers are Androgen-Responsive—Pioneering observations by Huggins (1941) demonstrated that many metastatic prostate cancers regress after surgical orchiectomy. Since then, androgen ab-

lation has been shown to induce temporary remission in approximately 80% of patients with metastatic prostate cancer, and has become a widely used treatment modality for this common disorder (Denis 1989; Neri et al, 1989; Beland et al, 1990; Schmitt et al, 2000). Suppression of testosterone concentrations, or action by surgical castration, or by administration of a gonatotropin-receptor hormone (GnRH) agonist, GnRH antagonist, antiandrogen, or estrogen is determined the basis of hormonal therapy of metastatic prostate cancer. Conversely, a study (Fowler and Whitmore 1981) of patients with metastatic prostate cancer documented tumor progression in 33 of 34 patients who received testosterone supplementation, and whose disease had relapsed prior to testosterone treatment. Thus, androgen ablation initially causes a remission in most men with prostate cancer, and androgen supplementation causes metastatic prostate cancer to flare.

The Effect of Testosterone Supplementation on the Course of Subclinical Prostate Cancers Is Unknown— Many aging men with normal serum levels of testosterone will have occult prostate cancers that never become clinical prostate cancers (Guileyardo et al, 1980; Carter et al, 1990; Sakr et al, 1994). The percentage of men with occult prostate cancers at autopsy increases with age and is >50% in the latter decades of life. The prevalence of occult prostate cancer is similar in American and Japanese men living in Japan (Carter et al, 1990). However, the incidence of clinical prostate cancer was 137.0 and 100.8 per 100 000 in American blacks and whites, respectively, and 9.0 per 100 000 in Japanese men living in Japan (Hsing and Devesa 2001). Available data do not indicate a significant difference in serum levels of testosterone among older men of different ethnic groups. It has been hypothesized that greater transcriptional activity of androgen receptor due to polymorphisms of the polyglutamine tract length in exon 1 of the receptor protein (Hardy et al, 1996; Giovannucci et al, 1997; Menin et al, 2001), or amplification of androgen action because of polymorphisms of the steroid 5 alpha-reductase (SRD5A2) locus (Margiotti et al, 2000; Hsing et al, 2001), which encodes the human prostatic (or type II) steroid 5 alpha-reductase enzyme, might contribute to some of the increased risk of prostate cancer in some high-risk groups.

Mortality due to prostate cancer varies inversely with age (Gatling, 1990), and most occult prostate cancers do not become clinical prostate cancers. Many of the occult cancers must occur in eugonadal men, however, it is not known whether the androgen deficiency that is associated with aging reduces the risk of an occult prostate cancer becoming a clinical prostate cancer. It is possible that testosterone administration might cause these latent or occult prostate cancers to grow and become clinically significant prostate cancer. Currently, we do not know the long-term

effects of testosterone replacement on occult prostate cancers.

In prospective, randomized controlled trials and retrospective reviews of clinical experience (Tenover 1992, 1998; Morley et al, 1993; Sih et al, 1997; Snyder et al, 1999a,b; Kenny et al, 2001), the total number of prostate cancers has not been numerically greater in testosterone-treated men than in placebo-treated men. However, all of the published studies (Tenover 1992, 1998; Morley et al, 1993; Sih et al, 1997; Snyder et al, 1999a,b; Kenny et al, 2001) have collectively treated fewer than 500 carefully selected, older men who had been rigorously screened for prostate cancer prior to treatment and meticulously followed. It will require a large clinical trial to assess the frequency with which testosterone supplementation might increase the frequency of clinically overt prostate cancers. For instance, to detect a 30% difference in the incidence rates of prostate cancers between testosterone-treated and placebo-treated men, approximately 6000 older men, 65–80 years of age, with low testosterone levels, will need to be randomized to each of the 2 treatment groups (placebo and testosterone). Assuming a 1.2% yearly incidence rate of newly diagnosed prostate cancers in men of this age group (Landis et al, 1998; Landis et al, 1999; Greenlee et al, 2000), the average treatment duration will have to be 5 years. A study of this magnitude, duration, and complexity would inevitably require allocation of substantial resources and infrastructure, but one is sorely needed to answer this crucial question about the safety of testosterone administration in older men.

Epidemiological Data on the Relationship Between Serum Testosterone Levels and Prostate Cancer

Epidemiological studies have failed to demonstrate a consistent, dose-related correlation between prostate cancer risk and sex hormone levels (Jackson et al, 1977, 1981; Ahluwalia et al, 1981; Meikle and Stanish 1982; Zumoff et al, 1982; Hulka et al, 1987; Nomura et al, 1988; Meikle et al, 1989; Barrett-Connor et al, 1990; Andersson et al, 1993; Hsing and Comstock 1993; Gann et al, 1996; Nomura et al, 1996; Demark-Wahnefried et al, 1997; Guess et al, 1997; Vatten et al, 1997; Wolk et al, 1997; Dorgan et al, 1998; Heikkila et al, 1999; Hawk et al, 2000; Shaneyfelt et al, 2000; Mohr et al, 2001; Slater, 2000). A majority of case-control studies have found no significant association between serum testosterone or dihydrotestosterone (DHT) concentrations and the risk of prostate cancer. Eaton and colleagues (1999) reported a quantitative review of the data from 8 prospective epidemiological studies and concluded that there are no large differences in circulating hormones between men who subsequently go on to develop prostate cancer and those who remain free of the disease. In a meta-analysis of 28 case control studies by Shaneyfelt et al (2000), 17 showed no differ-

ence between serum testosterone levels between men with prostate cancer and controls, 6 had lower testosterone levels, and only 6 showed higher levels. Remarkably, in 2 cohort and nested-case control studies (Nomura et al, 1988; Hsing and Comstock 1993; Gann et al, 1996), men with the higher quartile of serum testosterone concentrations, after adjustment for age, body mass index, DHT and estradiol, had 2.3 times the risk for prostate cancer than men in the lowest quartile. The increased risk is largely attributed to one study (Gann et al, 1996) in which low sex hormone-binding globulin (SHBG) levels were correlated with high serum testosterone levels, an unusual finding that is not reported in any other study. It also should be mentioned that 2 large, prospective, longitudinal studies of middle-aged and older men—the Rancho Bernardo Study—(Barrett-Connor et al, 1990) and the Massachusetts Male Aging Study (Mohr et al, 2001)—did not find a significant association or a dose-response relation between serum testosterone concentrations and the risk of prostate cancer.

None of the studies that measured DHT and estradiol found higher levels of these hormones in cases than in controls. SHBG levels have also not been significantly different between cases and controls in a majority of studies with the exception of one study (Gann et al, 1996).

Thus, the available evidence is conflicting and inconclusive on whether high testosterone concentrations confer a higher risk of prostate cancer in men. In many studies, the hormone measurements were performed on single, stored samples that were collected at different times of the day, which may have introduced a bias. The interpretation of data from epidemiological studies is confounded also by the variability in study design and methods for hormone measurements. The criteria used for selecting controls varied considerably and were not optimal in some studies. Many of the studies did not take into account the effects of prostate cancer and other concomitant illnesses on hormone levels, particularly in older men, and the high correlation between circulating concentrations of testosterone, estradiol, DHT, and SHBG. Finally, analyses of serum hormone levels does not take into account the possibility that circulating concentrations of hormones might not accurately reflect hormone action or concentrations at the tissue level, particularly within the prostate. An ongoing randomized, double-blind study of finasteride for the prevention of prostate cancer may provide important insights into the role of intraprostatic and circulating DHT concentrations in the pathophysiolgy of prostate cancer.

The problems inherent in epidemiological association studies have been highlighted recently by the firestorm that erupted after the release of data from the Women's Health Initiative on the effects of estrogen. The data from this and other randomized, controlled, intervention trials

have contrasted sharply with the data from previous epidemiological studies that had reported lower cardiovascular mortality in estrogen users. The results of the Women's Health Initiative (2002) and the HERS (Hulley et al, 1998) emphasize the need for definitive, randomized, placebo-controlled studies of testosterone supplementation in older men.

Biopsy-Diagnosed Prostate Cancer in Men with Low Testosterone Levels

Morgentaler et al (1996) evaluated 77 men with low total testosterone or free testosterone (measured by a tracer analogue assay) concentrations. These men with a mean age of 58 years had a normal digital rectal examination of the prostate, a PSA level of ≤4.0 ng/mL, and underwent sextant biopsies of the prostate. Eleven of 77 men (14%) were found to have prostate cancer with Gleason scores of 6 or 7. Serum PSA concentrations, PSA density, prostate volume, and total or free testosterone concentrations were not significantly different between men who had cancer and those who did not. This study did not have a control group, and we do not know whether sextant biopsies of age-matched controls with normal testosterone levels would yield a similarly high incidence of biopsy-detectable cancer. In another study of 332 men whose mean age was 64.2 years and who had PSA levels 2.6 to 4.0 ng/mL and a benign prostate examination, cancer was found in 22% of the biopsies (Catalona et al, 1997). In 2 additional studies, positive biopsies were found in 24% of 273 (Djavan et al, 1999) and 24% of 151 men (Babaian et al, 2001) with PSA levels between 2.5 and 4.0 ng/mL and a normal digital examination of the prostate. Therefore, the study by Morgenthaler et al (1996) should not be interpreted to indicate that there is an increased prevalence of latent prostate cancer in men with low free or total testosterone levels, or that prostate biopsies are needed in all men with low testosterone concentrations.

Two reports found a higher prevalence of prostate cancer in the biopsies and a higher histological prostate cancer score in men with low testosterone levels (Hoffman et al, 2000; Schatzl et al, 2001). Hoffman and colleagues (2000) evaluated 117 consecutive patients diagnosed with prostate cancer; 57 of these 117 men subsequently underwent radical prostatectomy. Men with low testosterone levels were older (69 vs 61.9 years), had a higher percentage of biopsies that revealed cancer (43% vs 22%, $P < .01$), and had a higher percentage of biopsies with a Gleason score of 8 or greater (7 of 64 vs 0 of 48, $P < .025$). Another study (Schatzl et al, 2001) reported that in men with prostate cancer, low testosterone levels are associated with somewhat higher-grade prostate cancers than in men with normal testosterone levels even though age, PSA level, and prostate volume were similar in the men with low and normal testosterone levels. These stud-

ies selected men who were diagnosed with prostate cancer and then analyzed the tumor characteristics on the basis of patients' serum levels of testosterone. Lack of appropriate controls that are matched for nutritional state and body composition makes it difficult to interpret these data. These data emphasize the need to be vigilant about the risk of prostate cancer even in men with low testosterone levels; however, these data should not be interpreted to indicate that low testosterone levels are a risk factor for prostate cancer.

Interpreting Changes in Serum PSA Levels During Testosterone Replacement Therapy

Data from Intervention Studies of Testosterone Replacement in Young and Older Men With Hypogonadism—Lowering of serum testosterone concentrations by withdrawal of androgen therapy in young men with hypogonadism is associated with a decrease in serum PSA levels (Meikle, 1997). Similarly, treatment of men with BPH with a 5-alpha reductase inhibitor, finasteride, is associated with a significant lowering of serum and prostatic PSA levels (Gormley et al, 1992).

Conversely, several studies (Holmang et al, 1993; Behre and Nieschlag, 1994; Gooren 1994; Douglas et al, 1995; Arver et al, 1997; Meikle et al, 1997; Ozata et al, 1997; Svetec et al, 1997; Bhasin et al, 1998; Wang et al, 2000; Jin et al, 2001; Shibasaki et al, 2001; Singh et al, 2001; Hong and Ahn 2002) of testosterone replacement in healthy young men with hypogonadism have demonstrated a significant increase in serum PSA levels after testosterone administration (Table 1), although some studies have reported no significant change in PSA levels (Cooper et al, 1996; Katznelson et al, 1996; Snyder et al, 2000). In a systematic review of published studies of testosterone replacement in men with hypogonadism, we have calculated the weighted effect size to be 0.68 standard deviation units with a 95% confidence interval of 0.55 to 0.82, which is statistically significant. This means that the average effect of testosterone replacement therapy is to increase PSA levels by about 0.68 standard deviations over baseline. Because the average standard deviation was 0.47 in this systematic analysis, the standard deviation score of 0.68 translates into an average increase in serum PSA levels of about 0.30 ng/mL. There is considerable variability in the magnitude of change in PSA after testosterone supplementation among these studies ($P < .00001$), in part due to the heterogeneity of study populations, inclusion of older men in some studies but not others, and differences in PSA assays. In addition, many patients who were enrolled in these studies were likely receiving testosterone replacement therapy previously; we do not know whether the washout period was sufficient to revert PSA levels to baseline. Therefore, it is possible that because of inadequate washout, the increments in se-

rum PSA levels after testosterone administration might have been underestimated.

To evaluate whether older men experience a greater increase in PSA after testosterone supplementation, we performed a separate systematic review of data from placebo-controlled trials of testosterone supplementation in older men with low or low-normal testosterone concentrations (Tenover 1992; Morley et al, 1993; Urban et al, 1995; Sih et al, 1997; Snyder et al, 1999a; Kenny et al, 2001). The weighted effect size in 6 studies of older men was 1.48 standard deviation units, with a 95% confidence interval of 1.21 to 1.75, which was statistically significant. Thus, on average, older men experience a greater increase in serum PSA concentrations than populations of predominantly younger men. The average effect of testosterone replacement in older men is to increase PSA levels by almost 1.5 standard deviations over baseline. There is, however, significant variability in the results among these 6 studies ($P < .0001$), and the average standard deviation was skewed by 1 study, which had a very high standard deviation (Kenny et al, 2001). After excluding this study, the average change in serum PSA levels after testosterone replacement in studies of older men was 0.43 ng/mL.

In the long-term, randomized, placebo-controlled trials of testosterone supplementation in older men (Sih et al, 1997; Snyder et al, 1999a,b; Kenny et al, 2001), the changes in PSA levels in testosterone-treated men were not significantly different from that in placebo-treated men (Table 2). Two short-term clinical trials of testosterone supplementation in older men (Tenover 1992; Urban 1999) did report statistically significant increments in PSA levels after testosterone treatment, although the increments in PSA levels were modest; serum PSA level increased from 2.1 to 2.7 ng/mL in one trial (Tenover 1992), and from 1.7 to 2.1 ng/mL in the other trial (Urban 1999).

In young men with eugonadism, administration of supraphysiological doses of testosterone does not further increase serum PSA levels (Bhasin et al, 1996; Wu et al, 1996). These data are consistent with dose-response studies in young men (Bhasin et al, 2001) that demonstrate that maximal serum concentrations of PSA are achieved at testosterone levels that are at the lower end of the normal male range; higher testosterone concentrations are not associated with higher PSA levels.

These data taken together suggest that the administration of replacement doses of testosterone in men with androgen deficiency can be expected to produce a modest increment in serum PSA levels. Increments in PSA levels after testosterone supplementation in men with androgen deficiency are generally less than 0.5 ng/mL, and increments in excess of 1.0 ng/mL over a 3–6 month period are unusual. Nevertheless, administration of testosterone

Table 1. *Change in serum PSA concentrations in healthy, hypogonadal men after testosterone replacement therapy*

Study	Subjects	Treatment	Change in PSA during treatment
Behre et al, 1994	Healthy, young hypogonadal	Testosterone enanthate 250 mg/2 wk, T patch or TU	+0.34 ng/mL
Cooper et al, 1996	Eugonadal men	Testosterone enanthate 11, 250, and 500 mg/2 wk	−0.1 ng/mL at 16 wk, −0.2 ng/mL at 28 wk, and +0.02 ng/mL at 40 wk, statistically insignificant
Meikle et al, 197	Healthy, hypogonadal men	Androderm patch 5.0 mg/day	+0.15 ng/mL after 12 mo of treatment
Wang et al, 2000†	Healthy, hypogonadal men, mostly young, but some older men included	Testosterone gel or androderm patch	+0.17 ng/mL after 3 mo, and +0.18 ng/mL after 6 mo of 50 mg/day testosterone gel treatment; +0.30 ng/mL after 3 and 6 mo of 100 mg/day testosterone gel; −0.01 ng/mL after 6 mo of testosterone patch
Synder et al, 2000	Healthy, older men with serum testosterone <475 ng/dL	Testosterone scrotal patch 6 mg/day	No change in PSA
Katznelson et al, 1996	Healthy, hypogonadal men	Testosterone enanthate or cypionate 100 mg/week	No significant change in PSA
Svetec et al, 1997	Men with erectile dysfunction, a normal digital rectal examination, and a low or low-normal total testosterone	Variable, individualized, replacement regimens	Mean increase in PSA after testosterone replacement was 0.29 ng/mL. Mean PSA velocity was 0.05 ng/mL per y.
Arver et al, 1997	Healthy, hypogonadal men	5 mg torso patch or testosterone enanthate	Actual values or change not given; however, PSA values were lower during patch treatment than during TE treatment
Bhasin et al, 1998	Young, HIV-infected men with serum testosterone less than 400 ng/dL	5 mg torso patch	Mean change +0.05 ng/mL, not significantly different than placebo
Singh et al, 2001	Men with end-stage renal disease on hemodialysis with total testosterone <350 ng/dL	10 mg torso patch	No significant change in PSA
Guay et al, 2000	90 men with erectile dysfunction and low testosterone levels	Variable, including testosterone enanthate, testosterone patch or clomiphene citrate	With testosterone patch, i.m. testosterone ester, and clomiphene, the mean increases in PSA were 0.20, 0.32, and 0.80 in men 40–60 y, and 0.23, 0.94, and 1.2 ng/mL in men 61–80 y of age
Douglas et al, 1995	10 hypogonadal men, 40–76 y	Testosterone enanthate 200 mg i.m. every 2 wk or 6 mg Testoderm patch	Increase in PSA from 0.98 to 1.42 ng/mL in testosterone patch group, and no change in testosterone enanthate group
Ozata et al, 1997	13 men with idiopathic hypogonadotropic hypogonadism (21–23 y)	hCG and hMG	Increase in PSA from 1.0 to 1.25 ng/mL
Shibasaki et al, 2001	Men with Klinefelter syndrome	Variable regimens of testosterone replacement	No change in serum PSA concentrations
Jin et al, 2001	71 hypogonadal men (range 18–78 y) compared with age-matched healthy controls without prostate disease	Testosterone esters, implants, and other modalities, treated for 1–145 mo	PSA levels after testosterone replacement similar to age-matched eugonadal controls, increased from 0.6 to 1.0 ng/mL
Hong and Ahn, 2002	Korean men with partial androgen deficiency	Oral testosterone undecanoate 160 mg daily for 3 wk, then 80 mg daily for 3 mo	No significant change in PSA levels
Holmang et al, 1993	23 middle-aged men, 40–65 y, BMI >25 kg/m²	Testosterone undecanoate 160 mg daily vs placebo × 8 mo	No significant change in PSA (from 1.28 to 1.30 μg/L after 8 mo)
Gooren, 1994	35 hypogonadal men; 33 followed for 10 y, 15–62 y	Testosterone undecanoate 80–200 mg daily	PSA not reported, urine flow rate did not change.

* We evaluated studies of testosterone replacement in healthy, hypogonadal men that were listed in the National Library of Medicine's PubMed database. For this systematic analysis, we included only those studies that reported PSA levels in the published manuscript. Although most of the studies included predominantly young men, some studies included men >age of 60. Studies that exclusively recruited older men are listed in Table 2.

† Testosterone gel used in this clinical trial employed a slightly different delivery system and concentration than the testosterone gel that is now commercially available.

Table 2. *Change in serum PSA concentrations in older men with low or low-normal testosterone concentrations**

Study	Subjects	Treatment	Change in PSA during treatment
Snyder et al, 1999	Healthy, older men with low normal or low testosterone levels	Scrotal testosterone patch 6 mg/day × 3 y	PSA increased from a mean of 1.5 to 2.0 ng/mL at 6 mo, and remained stable thereafter
Sih et al, 1997	Healthy older men with bio-testosterone <70 ng/dL	Testosterone cypionate 200 mg/14–17 days × 12 mo	PSA increased from a mean of 1.0 ng/mL at baseline to 1.3 ng/mL at 3 mo, 1.6 ng/mL at 6 mo, and 1.9 ng/mL at 12 mo. Change in testosterone-treated men not significantly different from placebo-treated men
Urban et al, 1999	Healthy, older men, with low normal testosterone levels	Initial testosterone enanthate dose 100 mg weekly; dose adjusted. Duration 4 wk	Mean PSA increased significantly from 1.7 ng/mL to 2.1 ng/mL ($P = .04$). No placebo group for comparison
Morley et al, 1993	Medically stable, older men with biotestosterone <70 ng/dL	Testosterone enanthate 200 mg every 2 wk × 3 mo	Mean PSA increased from 1.7 ng/mL to 2.5 ng/mL; ($P = $ NS)
Tenover et al, 1992	Healthy, older men with testosterone <350 ng/dL	Testosterone enanthate 100 mg weekly × 3 mo	Significant increase in PSA from a mean of 2.1 ng/mL to 2.7 ng/mL ($P < .01$)
Kenny et al, 2001	67 men (range 65–87) with bioavailable testosterone levels <4.44 nmol/L	Placebo vs 5 mg/day testosterone patch	2.0 ± 1.4 ng/mL to 2.6 ± 1.8 µg/L ($P < .04$)
Hajjar et al, 1997	Retrospective analysis of men with erectile dysfunction and bioavailable testosterone <72 ng/dL	Testosterone enanthate or cypionate 200 mg every 2 wk. Controls received no treatment	+0.49 ng/mL in testosterone-treated men vs +0.25 ng/mL in placebo-treated men; difference between placebo and testosterone-treated men was not statistically significant

* For this systematic analysis, we included those studies that exclusively recruited healthy, older men with low or low-normal testosterone concentrations, and were listed in the National Library of Medicine's PubMed database. The age criteria for inclusion differed significantly among these studies. Similarly, treatment regimens, duration, and PSA inclusion criteria were not uniform across these studies.

to men with baseline PSA levels between 2.5 and 4.0 ng/mL will cause PSA levels to exceed 4.0 ng/mL in some men. Increments in PSA levels above 4 ng/mL will trigger a urological consultation and many of these men will be asked to undergo prostate biopsies.

Variation in PSA Concentrations Due To Assay Variability and Aging-Related Change—There is considerable test-retest variability in PSA measurements. Some of this variability is due to the inherent assay variability, and a significant portion of this variability is due to unknown factors. Kadmon and colleagues (1996) determined the variability of serum PSA levels in men without prostate cancer. The interassay coefficient of variation was 7.5%. Fluctuations in serum PSA occurred in 78% of the men over a 2-year follow up period, and 12.5% had at least a single PSA increase exceeding 0.75 ng/mL per year. Fluctuations were larger with higher mean PSA levels. There is some evidence that the interassay variation is greater than 1 ng/mL in a significant percentage of samples assayed with the Hybritech assay (Manseck et al, 1998). Interassay variability is reported to be less with the Abbott Asym assay. Variability can be even greater if measurements are performed in different laboratories that use dissimilar assay methodologies (Riehmann et al, 1993; Wenzl et al, 1998). The 95% confidence limits for the change in PSA levels between 2 tests performed 3–6 months apart in the placebo-treated men in a study of finasteride in men with BPH was 1.4 ng/mL or 49% of baseline value (Gormley et al, 1992); therefore, a change of >1.4 ng/mL in samples drawn 3–6 months apart has been used as a criterion for seeking urological evaluation in some clinical trials of finasteride (McConnell et al, 1998). As a rough approximation, the interassay coefficient of variation of PSA assays on average has been reported to be 15% (Ornstein et al, 1997). The coefficient of variation of the PSA assay should be taken into account when evaluating the change in PSA between samples drawn at different times or when interpreting the PSA velocity (see *PSA Velocity Criteria* in section later).

Some types of prostatic manipulations such as prostatic massage, needle biopsy, and transurethral retrograde prostatectomy (TURP) can significantly increase PSA levels, whereas other procedures such as digital rectal examination, cystoscopy, and ejaculation have very little effect on serum PSA levels (Klein and Lowe 1997). These factors should be considered in the interpretation of elevated PSA levels.

Application of the PSA Velocity Criterion to Prostate Monitoring During Testosterone Administration—In patients in whom sequential PSA measurements are available for more than 2 years, Carter and Pearson (1993) have proposed the use of PSA velocity criterion to iden-

tify men at higher risk for prostate cancer. A PSA velocity criterion has not been used in any of the published clinical trials of testosterone supplementation. Based on the analysis of the data of men in the Baltimore Longitudinal Study of Aging, Carter et al (1995) demonstrated that if the baseline PSA were between 4 and 10 ng/mL, a rate of change of >0.75 ng/mL/y in PSA was unusual in men with benign prostatic disease. Because most men receiving testosterone replacement will have baseline PSA levels <4.0 ng/mL, the criteria established for baseline PSA values between 4 and 10 ng/mL are too lenient. In a recent analysis of data from the Baltimore Longitudinal Aging Study, Fang et al (2002) reported the PSA velocity in men with prostate cancers who have baseline PSA <4 ng/mL. In these men with initial PSA of less than 4 ng/mL, the long-term follow-up indicated that a cut point for PSA velocity of 0.1 ng/mL per year had a sensitivity of 81% and a specificity of 50% for the detection of prostate cancer. Setting the threshold at 0.2 ng/mL per year gave a sensitivity of 52.4% and a specificity of 79.4%. These findings need to be confirmed; however, it should be recognized that in view of the considerable test-retest variability in PSA levels in the same individual, setting thresholds for prostate biopsy that are substantially lower than the test-retest variability would likely result in a large number of false triggers for biopsy.

The use of PSA velocity criterion is likely to be more useful in men in whom PSA data are available over many years so that the PSA change over baseline exceeds the expected interassay variability. As an illustration, consider the case of a man with baseline PSA of 2.4 ng/mL and whose PSA after 2 years of testosterone supplementation is 3 ng/mL. The absolute 2-year change in PSA of 0.6 ng/mL translates into a PSA velocity of 0.3 ng/mL/y, and exceeds the threshold of 0.2 ng/mL/y proposed by Fang et al (2002). However, because this change of 0.6 ng/mL is less than 2 times the interassay CV (30% or 0.72 ng/mL), it should be viewed with caution and followed by closer follow-up of PSA values over the subsequent year rather than immediate prostate biopsy. It should be emphasized that the study by Fang et al (2002) involved a relatively small number of men who developed prostate cancer over a long period (10 years) of follow up. In another study a PSA velocity cutoff of 0.75 ng/mL or more per year provided a sensitivity of 79% and a specificity of 66% in predicting prostate cancer (Smith and Catalona 1994). These observations came from a prostate cancer detection study that involved 312 men with baseline PSA levels of <4.0 ng/mL and who subsequently developed PSA values >4.0 ng/mL. All men with verified PSA levels >4.0 ng/mL underwent prostate biopsies. Follow-up was for up to 5 years.

Carter and Pearson (1993) have emphasized that PSA velocity should not be used for follow-up periods of less than 2 years. Also, estimation of PSA velocity requires multiple PSA measurements over time. PSA velocity is calculated as the total change in PSA from baseline divided by the time in years. A PSA velocity of >0.2 ng/mL/y does not imply that the patient has prostate cancer, nor should it be used to dictate immediate prostate biopsy; rather, it signifies a higher than average risk for developing prostate cancer during the subsequent decades Therefore, PSA velocity can be particularly useful during long-term follow-up of patients over many years. For periods of less than 3 years, we propose that PSA velocity of >0.4 ng/mL/y should warrant a urological evaluation and more intensive future surveillance for prostate cancer. For follow-up periods exceeding 3 years, a PSA velocity of >0.2 ng/mL/y is likely associated with a greater than average risk of prostate cancer and should warrant a closer follow-up of the patient. Neither of these PSA velocity criteria that we have proposed has been tested for specificity or sensitivity in prospective trials of testosterone replacement; they should be viewed as the authors' opinions based on a relatively limited amount of data.

Effects of Testosterone Supplementation on Prostate Volume and Course of BPH—Prostate size increases during the pubertal years; after completion of pubertal growth, there is little change in prostate size until approximately 50 years of age. After 50 years of age, prostate size begins to increase again (Berry et al, 1984). Histological BPH is uncommon in men in their 30s and 40s, and its prevalence increases with age so that by age 80, about 80% of men have histological evidence of BPH. About half of these men develop macronodular BPH. There is no clear correlation between serum androgen concentrations and prostate size in men. As men age, the prostate volume increases, whereas serum total and free testosterone concentrations decrease. Most but not all studies have found that mean serum DHT and estradiol levels remain relatively constant in men with advancing age. There is, however, a correlation between prostate volume and PSA. The PLESS study showed that baseline PSA and prostate volume are powerful predictors of the risk of acute urinary retention and the need for BPH-related surgery (Roehrborn et al, 2000).

Lowering of serum testosterone concentrations by administration of a GnRH agonist, or blocking androgen effects by administration of an antiandrogen is associated with a reduction in prostate volume. These treatments are typically associated with a 20%–30% reduction in prostate volume. Inhibition of steroid 5-alpha-reductase enzyme by finasteride decreases serum and intraprostatic DHT concentration, and was associated with an average 16% reduction in prostate volume in a large multicenter study (Gormley et al, 1992). Thus, once established, androgen deprivation is moderately effective in reducing prostate volume.

In young men with hypogonadism, prostate volumes are lower than in age-matched controls, and testosterone replacement therapy increases prostate volume to that of age-matched controls (Behre, 1994; Meikle, 1997). However, continued treatment with replacement doses of testosterone does not increase prostate volume progressively or above the size expected for age. Treatment of BPH usually is guided by the severity of symptoms, and prostate volume and symptoms usually are not closely correlated. In placebo-controlled, randomized, clinical trials of testosterone in older men with low or low-normal testosterone levels (Sih et al, 1997; Tenover 1998; Snyder et al, 1999a,b), there were no significant differences in the frequency of prostate events or invasive procedures between placebo and testosterone-treated men. Although 2 of the randomized clinical trials were of 3 years duration (Tenover 1998; Snyder et al, 1999a,b), none of the previous studies was powered to detect clinically meaningful differences in prostate event rates. They did not involve a large enough number of men for a long enough time to answer this issue. Therefore, we do not know whether testosterone replacement therapy will increase the need for invasive treatment of BPH.

Testosterone replacement can be administered safely to men with BPH who have mild to moderate symptom scores (Table 4). The severity of symptoms associated with BPH can be assessed by using either the International Prostate Symptom Score (IPSS) or the American Urological Association (AUA) Symptom questionnaires. Because androgen replacement in men with androgen deficiency increases prostate volumes only modestly (Sasagawa, 1990; Behre, 1994; Cooper et al, 1996; Meikle, 1997), there is typically little or no change in prostate symptom scores in most men treated with replacement doses of testosterone. However, it is possible that in patients with pre-existing, severe symptoms of BPH, even small increases in prostate volume during testosterone administration may exacerbate obstructive symptoms. In these men, testosterone should either not be administered or it should be administered with careful monitoring of their obstructive symptoms and only after their prostatic enlargement has been effectively treated urologically.

Use of Other Prostate Markers for Monitoring—The utility of measurements of free and complexed PSA for prostate cancer screening has been investigated in several trials (Polascik et al, 1999; Djavan et al, 2002; Ellison et al, 2002); these studies generally suggest that percent free PSA improves the specificity for prostate cancer detection in men with PSA values between 4 and 10 ng/mL. However, these studies have not demonstrated higher predictive value with the use of algorithms that employ digital rectal examination, total PSA, and the ratio of free to total PSA over algorithms that use only digital rectal examination and total PSA. The cost:benefit analyses have yet

Table 3. *Recommendations for monitoring prostate-related, adverse experiences during testosterone replacement in older men*

A. Baseline evaluation
   1. Digital rectal examination
   2. Serum PSA
   3. AUA or IPSS symptom scores for benign prostatic hyperplasia
B. Follow-up evaluation at 3, 6, and 12 mo and annually thereafter
   1. Serum PSA
   2. Digital rectal examination
   3. AUA or IPSS symptom scores for benign prostatic hyperplasia

AUA indicates American Urological Association; IPSS, International Prostate Symptom Score.

to establish the utility of using free to total PSA ratio or complexed PSA in population screening for prostate cancer.

Some studies have suggested that a PSA density of greater than 0.15 may better distinguish BPH from prostate cancer (Polascik, 1999) than PSA alone; the predictive value and cost effectiveness of such as an approach for population screening of older men has not been evaluated in large, prospective, clinical trials. The calculation of PSA density requires the measurement of prostate volume by the use of ultrasound; this adds significantly to the cost of screening. In addition, no data are currently available from testosterone trials to rationalize the use of either free to total PSA ratio or PSA density in prostate screening during testosterone supplementation.

Monitoring Recommendations

Monitoring PSA Levels in Older Men Receiving Testosterone Replacement—Older men considering testosterone supplementation should undergo digital examination of the prostate, evaluation of risk factors for prostate cancer, and symptom scores for BPH using either the AUA or the IPSS questionnaire, and a baseline PSA measurement (Table 3). As a general rule, men with a previous history of prostate cancer should not be given androgen supplementation, and those with palpable abnormalities of the prostate or PSA levels >4 ng/mL should undergo urological evaluation (Table 4). We recognize that some men with hypogonadism who have had a radical prostatectomy for prostate cancer and undetectable PSA levels for several years may be "cured" and may be candidates for testosterone replacement therapy. Because testosterone administration could potentially promote the growth of residual cancer, replacement therapy in this setting should only be considered after urological consultation and after a thorough discussion of the potential risks. If replacement therapy is provided to such men, PSA levels must be monitored more frequently. Men with BPH and mild to moderate symptoms of (AUA symptom score less than 21) can be safely treated with testosterone replacement with careful follow-up.

Table 4. *Prostatic disorders that constitute relative or absolute contraindications for androgen supplementation*

Absolute contraindication

1. The presence or history of prostate cancer

Relative contraindications

1. Baseline PSA 4 ng/mL or a palpable abnormality of the prostate without urological evaluation to rule out prostate cancer
2. Evidence of hereditary prostate cancer in men, defined as the presence of 3 or more affected relatives within a nuclear family, or occurrence of prostate cancer within each of 3 generations (paternal or maternal), or the presence of 2 relatives affected at an early age of 55 y or less (Carter et al, 1993)
3. Severe symptoms of lower urinary tract obstruction as indicated by IPSS or AUA symptoms core of 21 or greater

Table 5. *Indications for urological consultation in men receiving testosterone replacement*

1. Verified serum or plasma PSA concentration >4.0 ng/mL
2. An increase in serum or plasma PSA concentration >1 ng/mL after 3 or 6 mo of testosterone treatment
3. A PSA velocity of >0.4 ng/mL/y using the PSA level after 6 mo of testosterone administration as the reference*
4. Detection of a prostatic abnormality on digital rectal examination
5. An AUA or IPSS prostate symptom score of >21

* The recommendation for using PSA velocity threshold of 0.4 ng/mL/y is not based on data, but it takes into consideration the findings of Fang et al (2002) and those of Smith and Catalona (1994). It reflects our opinion based on considerations of interassay coefficient of variation of PSA assays and these 2 reports.

After initiation of testosterone replacement therapy, PSA levels and digital examination of the prostate should be repeated at 3, 6, and 12 months, and annually thereafter (Andropause Consensus Panel, 2001). Clinical experience and data from controlled clinical trials have established that the increments in PSA levels after testosterone administration in men with hypogonadism occur in the first 3–6 months, at which point new steady state PSA levels are achieved. Continued treatment beyond 12–24-weeks would be expected to be associated only with predictable, age-related changes in PSA levels. Therefore, excessive increases in serum PSA levels after 3–6 months of initiating testosterone replacement therapy should be investigated. Our recommendations for requesting a urological consultation are provided in Table 5.

Men being considered for testosterone replacement therapy should also be evaluated for prostate symptom scores by using the AUA or the IPSS symptom questionnaires. Testosterone should not be administered to men with symptoms scores in excess of 21. These symptom scores should be re-evaluated 3 months after initiating testosterone replacement therapy, and annually thereafter. Marked increases in PSA symptom scores or increases above 21 during treatment should lead to urological evaluation.

Other Uncertainties Related to Testosterone Supplementation in Older Men

Although this review focused on issues related to potential prostate adverse events and monitoring during testosterone replacement of older men, a number of other uncertainties are related to the issue of testosterone supplementation, which have been discussed in other recent reviews (Andropause Consensus Panel 2001; AACE Guidelines for Evaluation and Treatment of Hypogonadism in Adult Male Patients 2002 Update; Bhasin and Buckwalter 2001; Matsumoto 2002; American College of Medicine, 2002; Morales and Lunenfeld 2002), but were not covered in this systematic review. There is no con-

sensus on numerical thresholds of serum total or free testosterone concentrations, which should be used to define ''androgen deficiency'' in older men. However, most authorities compare levels with those in healthy men 20 to 40 or 45 years of age. The beneficial effects of testosterone replacement in older men on health-related outcomes are yet to be demonstrated. We do not know the optimum target level of serum testosterone that should be achieved during testosterone replacement and that would maximize benefits and minimize the risks of testosterone supplementation. The role of androgen supplements—DHEA and androstenedione—which are widely available in health food stores, remains largely unknown.

Acknowledgments and Disclaimers

References

American Association for Clinical Endocrinologists. AACE Guidelines for evaluation and treatment of hypogonadism in adult male patients − 2002 update. *Endocr Pract.* 2002;8:439–456.

Ahluwalia B, Jackson MA, Jones GW, Williams AO, Rao MS, Rajguru S. Blood hormone profiles in prostate cancer patients in high-risk and low- risk populations. *Cancer.* 1981;48:2267–2273.

American College of Physicians/American Society of Internal Medicine. Disease Management Module on Male Hypogonadism. 2002.

Andersson SO, Adami HO, Bergstrom R, Wide L. (1993). Serum pituitary and sex steroid hormone levels in the etiology of prostatic cancer—a population-based case-control study. *Br J Cancer.* 1993;68: 97–102.

Andropause, Consensus Panel. *Proceedings of the Andropause Consensus Panel,*. The Endocrine Society; 2001.

Arver S, Dobs AS, Meikle AW, Caramelli KE, Rajaram L, Sanders SW, Mazer NA. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. *Clin Endocrinol (Oxf).* 1997;47:727–737.

Babaian RJ, Johnston DA, Naccarato W, Ayala A, Bhadkamkar VA, Fritsche HA Jr. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relation to biopsy strategy. *J Urol.* 2001;165:757–760.

Barrett-Connor E, Garland C, McPhillips JB, Khaw KT, Wingard DL. A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. *Cancer Res.* 1990;50:169–173.

Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. *Clin Endocrinol (Oxf).* 1994;40:341–349.

Beland G, Elhilali M, Fradet Y, Laroche B, Ramsey EW, Trachtenberg J, Venner PM, Tewari HD. A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma. *Cancer.* 1990; 66(5 suppl):1074–1079.

Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. *J Urol.* 1984;132:474–479.

Bhasin S, Buckwalter JG. Testosterone supplementation in older men: a rational idea whose time has not yet come. *J Androl.* 2001;22:718–731.

Bhasin S, Storer TW, Asbel-Sethi N, et al. Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels. *J Clin Endocrinol Metab.* 1998;83:3155–3162.

Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men [see comments]. *N Engl J Med.* 1996;335:1–7.

Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. *Am J Physiol Endocrinol Metab.* 2001;281:E1172–E1181.

Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, Walsh PC. Hereditary prostate cancer: epidemiologic and clinical features. *J Urol.* 1993;150:797–802.

Carter HB, Pearson JD. PSA velocity for the diagnosis of early prostate cancer. A new concept. *Urol Clin North Am.* 1993;20:665–670.

Carter HB, Pearson JD, Waclawiw Z, Metter EJ, Chan DW, Guess HA, Walsh PC. Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. *Urology.* 1995;45:591–596.

Carter HB, Piantadosi S, Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. *J Urol.* 1990;143:742–746.

Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. *JAMA.* 1997;277:1452–1455.

Coley CM, Barry MJ, Fleming C, Wasson JH, Fahs MC, Oesterling JE. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part II: early detection strategies. *Urology.* 1995;46:125–141.

Cooper CS, MacIndoe JH, Perry PJ, Yates WR, Williams RD. The effect of exogenous testosterone on total and free prostate specific antigen levels in healthy young men. *J Urol.* 1996;156(2 part 1):438–442.

Demark-Wahnefried W, Lesko SM, Conaway MR, et al. Serum androgens: associations with prostate cancer risk and hair patterning. *J Androl.* 1997;18:495–500.

Denis L. LHRH analogues in combination with an anti-androgen in the treatment of advanced disease. *Horm Res.* 1989;32(suppl 1):66–68.

Djavan B, Zlotta A, Kratzik C, Remzi M, Seitz C, Schulman CC, Marberger M. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate can-cer in men with serum PSA 2.5 to 4.0 ng/mL. *Urology.* 1999;54:517–522.

Dorgan JF, Albanes D, Virtamo J, et al. Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in Finland. *Cancer Epidemiol Biomarkers Prev.* 1998;7:1069–1074.

Douglas TH, Connelly RR, McLeod DG, Erickson SJ, Barren R, Murphy GP. Effect of exogenous testosterone replacement on prostate-specific antigen and prostate-specific membrane antigen levels in hypogonadal men. *J Surg Oncol.* 1995;59:246–250.

Eaton NE, Reeves GK, Appleby PN, Key TJ. Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. *Br J Cancer.* 1999;80:930–934.

Fang J, Metter EJ, Landis P, Carter HB. PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml. *Urology.* 2002;59:889–894.

Fang J, Metter EJ, Landis P, Chan DW, Morrell CH, Carter HB. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. *Urology.* 2001;58:411–416.

Fowler JE Jr, Whitmore WF Jr. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. *J Urol.* 1981;126:372–375.

Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. *J Natl Cancer Inst.* 1996;88:1118–1126.

Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. *JAMA.* 1995;273:289–294.

Gatling RR. Prostate carcinoma: an autopsy evaluation of the influence of age, tumor grade, and therapy on tumor biology. *South Med J.* 1990;83:782–784.

Giovannucci E, Stampfer MJ, Krithivas K, et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. *Proc Natl Acad Sci USA.* 1997;94:3320–3323.

Gooren LJ. A ten-year safety study of the oral androgen testosterone undecanoate. *J Androl.* 1994;15:212–215.

Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group [see comments]. *N Engl J Med.* 1992;327:1185–1191.

Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. *CA Cancer J Clin.* 2000;50:7–33.

Guay AT, Perez JB, Fitaihi WA, Vereb M. Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer. *Endocr Pract.* 2000;6:132–138.

Guess HA, Friedman GD, Sadler MC, Stanczyk FZ, Vogelman JH, Imperato-McGinley J, Lobo RA, Orentreich N. 5 Alpha-reductase activity and prostate cancer: a case-control study using stored sera. *Cancer Epidemiol Biomarkers Prev.* 1997;6:21–24.

Guileyardo JM, Johnson WD, Welsh RA, Akazaki K, Correa P. Prevalence of latent prostate carcinoma in two U.S. populations. *J Natl Cancer Inst.* 1980;65:311–316.

Haffner SM, Shaten J, Stern MP, Smith GD, Kuller L. Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. *Am J Epidemiol.* 1996;143:889–897.

Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. *J Clin Endocrinol Metab.* 1997;82:3793–3796.

Hardy DO, Scher HI, Bogenreider T, Sabbatini P, Zhang ZF, Nanus DM, Catterall JF. Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. *J Clin Endocrinol Metab.* 1996;81:4400–4405.

Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitu-

dinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. *J Clin Endocrinol Metab.* 2001;86:724–731.

Hawk E, Breslow RA, Graubard BI. Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the first National Health and Nutrition Examination Survey. *Cancer Epidemiol Biomarkers Prev.* 2000;9:523–527.

Heikkila R, Aho K, Heliovaara M, Hakama M, Marniemi J, Reunanen A, Knekt P. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. *Cancer.* 1999;86:312–315.

Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? *J Urol.* 2000;163:824–827.

Holmang S, Marin P, Lindstedt G, Hedelin H. Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men. *Prostate.* 1993;23:99–106.

Hong JH, Ahn TY. Oral testosterone replacement in Korean patients with PADAM. *Aging Male.* 2002;5:52–56.

Hsing AW, Chen C, Chokkalingam AP, et al. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. *Cancer Epidemiol Biomarkers Prev.* 2001;10:1077–1082.

Hsing AW, Comstock GW. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. *Cancer Epidemiol Biomarkers Prev.* 1993;2:27–32.

Hsing AW, Devesa SS. Trends and patterns of prostate cancer: what do they suggest? *Epidemiol Rev.* 2001;23:3–13.

Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. *Int J Cancer.* 2000;85:60–67.

Huggins C, Hodges CV. Studies on prostate cancer I: the effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. *Cancer Res.* 1941;1:293–308.

Hulka BS, Hammond JE, DiFerdinando G, et al. Serum hormone levels among patients with prostatic carcinoma or benign prostatic hyperplasia and clinic controls. *Prostate.* 1987;11:171–182.

Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. *JAMA.* 1998;280:605–613.

Jackson MA, Ahluwalia BS, Herson J, et al. Characterization of prostatic carcinoma among blacks: a continuation report. *Cancer Treat Rep.* 1977;61:167–72.

Jackson MA, Kovi J, Heshmat MY, Jones GW, Rao MS, Ahluwalia BS. Factors involved in the high incidence of prostatic cancer among American blacks. *Prog Clin Biol Res.* 1981;53:111–132.

Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. *CA Cancer J Clin.* 2002;52:23–47.

Jin B, Conway AJ, Handelsman DJ. Effects of androgen deficiency and replacement on prostate zonal volumes. *Clin Endocrinol (Oxf).* 2001;54:437–445.

Kadmon D, Weinberg AD, Williams RH, Pavlik VN, Cooper P, Migliore PJ. Pitfalls in interpreting prostate specific antigen velocity. *J Urol.* 1996;155:1655–1657.

Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DL, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. *J Clin Endocrinol Metab.* 1996;81:4358–4365.

Kaufman JM, Vermeulen A. Declining gonadal function in elderly men. *Baillieres Clin Endocrinol Metab.* 1997;1:289–309.

Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men

with low bioavailable testosterone levels. *J Gerontol A Biol Sci Med Sci.* 2001;56:M266–M272.

Klein LT, Lowe FC. The effects of prostatic manipulation on prostate-specific antigen levels. *Urol Clin North Am.* 1997;24:293–297.

Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. *CA Cancer J Clin.* 1998;48:6–29.

Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. *CA Cancer J Clin.* 1999;49:8–31.

Manni A, Bartholomew M, Caplan R, et al. Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. *J Clin Oncol.* 1988;6:1456–1466.

Manseck A, Pilarsky C, Froschermaier S, Menschikowski M, Wirth MP. Diagnostic significance of prostate-specific antigen velocity at intermediate PSA serum levels in relation to the standard deviation of different test systems. *Urol Int.* 1998;60:25–27.

Margiotti K, Sangiuolo F, De Luca A, et al. Evidence for an association between the SRD5A2 (type II steroid 5 alpha-reductase) locus and prostate cancer in Italian patients. *Dis Markers.* 2000;16:147–150.

Matsumoto AM. Andropause: clinical implications of the decline in serum testosterone levels with aging in men. *J Gerontol A Biol Sci Med Sci.* 2002;57:M76–M99.

McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. *N Engl J Med.* 1998;338:557–563.

Meikle AW, Arver S, Dobs AS, et al. Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. *Urology.* 1997;49:191–196.

Meikle AW, Smith JA, Stringham JD. Estradiol and testosterone metabolism and production in men with prostatic cancer. *J Steroid Biochem.* 1989;33:19–24.

Meikle AW, Stanish WM. Familial prostatic cancer risk and low testosterone. *J Clin Endocrinol Metab.* 1982;54:1104–1108.

Menin C, Banna GL, De Salvo G, et al. Lack of association between androgen receptor CAG polymorphism and familial breast/ovarian cancer. *Cancer Lett.* 2001;168:31–36.

Mohr BA, Feldman HA, Kalish LA, Longcope C, McKinlay JB. Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study. *Urology.* 2001;57:930–935.

Morales A, Lunenfeld B. International Society for the Study of the Aging Male. Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. International Society for the Study of the Aging Male. *Aging Male.* 2002;5:74–86.

Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod DG, Moul JW. Age-specific reference ranges for prostate-specific antigen in black men. *N Engl J Med.* 1996;335:304–310.

Morgentaler ABC, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. *JAMA.* 1996;276:1904–1906.

Morley JE, Kaiser FE, Perry HM III, et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. *Metabolism.* 1997;46:410–413.

Morley JE, Perry HM III, Kaiser FE, Kraenzle D, Jensen J, Houston K, Mattammal M. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. *J Am Geriatr Soc.* 1993;41:149–152.

Neri B, Bartalucci S, Pieri A, Gemelli MT, Rizzo M, Bartoletti R, Trippitelli A, Paoletti MC. Complete androgen blockade as treatment for advanced prostate cancer: clinical response and side-effects. *Anticancer Res.* 1989;9:13–16.

Nomura A, Heilbrun LK, Stemmermann GN, Judd HL. Prediagnostic serum hormones and the risk of prostate cancer. *Cancer Res.* 1988;48:3515–3517.

Nomura AM, Stemmermann GN, Chyou PH, Henderson BE, Stanczyk

FZ. Serum androgens and prostate cancer. *Cancer Epidemiol Biomarkers Prev.* 1996;5:621–625.

Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. *JAMA.* 1993;270:860–864.

Ornstein DK, Smith DS, Rao GS, Basler JW, Ratliff TL, Catalona WJ. Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers. *J Urol.* 1997;157:2179–2182.

Ozata M, Bulur M, Beyhan Z, Sengul A, Saglam M, Turan M, Corakci A, Ali Gundogan M. Effects of gonadotropin and testosterone treatments on prostate volume and serum prostate specific antigen levels in male hypogonadism. *Endocr J.* 1997;44:719–724.

Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery—what we have learned and where we are going. *J Urol.* 1999;16:293–306.

Riehmann M, Rhodes PR, Cook TD, Grose GS, Bruskewitz RC. Analysis of variation in prostate-specific antigen values. *Urology.* 1993;42:390–397.

Roehrborn CG, McConnell J, Bonilla J, et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. *J Urol.* 2000;163:13–20.

Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, Haas GP. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20–69: an autopsy study of 249 cases. *In Vivo.* 1994;8:439–443.

Santen RJ, Manni A, English HF, Heitjan D. Androgen-primed chemotherapy-experimental confirmation of efficacy. *J Steroid Biochem Mol Biol.* 1990;37:1115–1120.

Sasagawa I, Kazama NT, Satomi S, Terada T, Katayama T. Volume change of the prostate and seminal vesicles in male hypogonadism after androgen replacement therapy. *Int Urol Nephrol.* 1990;22:279–284.

Schatzl G, Madersbacher S, Thurridl T, Waldmuller J, Kramer G, Haitel A, Marberger M. High-grade prostate cancer is associated with low serum testosterone levels. *Prostate.* 2001;47:52–58.

Schmitt B, Bennett C, Seidenfeld J, Samson D, Wilt T. Maximal androgen blockade for advanced prostate cancer. *Cochrane Database Syst Rev.* 2000;2.

Shaneyfelt T, Husein R, Bubley G, Mantzoros CS. Hormonal predictors of prostate cancer: a meta-analysis. *J Clin Oncol.* 2000;18:847–853.

Shibasaki T, Sasagawa I, Suzuki Y, Yazawa H, Ichiyanagi O, Matsuki S, Miura M, Nakada J. Effect of testosterone replacement therapy on serum PSA in patients with Klinefelter syndrome. *Arch Androl.* 2001;47:173–176.

Sih R, Morley JE, Kaiser FE, Perry HM III, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial [see comments]. *J Clin Endocrinol Metab.* 1997;82:1661–1667.

Singh AB, Norris K, Modi N, Sinha-Hikim I, Shen R, Davidson T, Bhasin S. Pharmacokinetics of a transdermal testosterone system in men with end stage renal disease receiving maintenance hemodialysis and healthy hypogonadal men. *J Clin Endocrinol Metab.* 2001;86:2437–2445.

Slater S, Oliver RT. Testosterone: its role in development of prostate

cancer and potential risk from use as hormone replacement therapy. *Drugs Aging.* 2000;17;431–439.

Smith DS, Catalona WJ. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. *J Urol.* 1994;152:1163–1167.

Smith KW, Feldman HA, McKinlay JB. Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men. *Clin Endocrinol (Oxf).* 2000;53:703–711.

Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. *J Clin Endocrinol Metab.* 2000;85:2670–2677.

Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. *J Clin Endocrinol Metab.* 1999a;84:1966–1972.

Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. *J Clin Endocrinol Metab.* 1999b;84:2647–2453.

Svetec DA, Canby ED, Thompson IM, Sabanegh ES Jr. The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction. *J Urol.* 1997;158:1775–1777.

Tenover JS. Effects of testosterone supplementation in the aging male. *J Clin Endocrinol Metab.* 1992;75:1092–1098.

Tenover JS. Testosterone for all? *The 80th Endocrine Society Meetings.* New Orleans, Louisiana, June 24–27, 1998; abstract S-8–1.

Urban RJ. Effects of testosterone and growth hormone on muscle function. *J Lab Clin Med.* 1999;134:7–10.

Urban RJ, Bodenburg YH, Gilkison C, Foxworth J, Coggan AR, Wolfe RR, Ferrando A. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. *Am J Physiol.* 1995;269(5 part 1):E820–E826.

Vatten LJ, Ursin G, Ross RK, Stanczyk FZ, Lobo RA, Harvei S, Jellum E. Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway. *Cancer Epidemiol Biomarkers Prev.* 1997;6:967–969.

Wang C, Swedloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group [In Process Citation]. *J Clin Endocrinol Metab.* 2000;85:2839–2853.

Wenzl TB, Riehmann M, Cook TD, Bruskewitz RC. Variation in PSA values in patients without malignancy. *Urology.* 1998;52:932.

Wolk A, Andersson SO, Bergstrom R. Prospective study of sex hormone levels and risk of prostate cancer. *J Natl Cancer Inst.* 1997;89:820.

Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. *JAMA.* 2002;288:321–333.

Wu FC, Farley TM, Peregoudov A, Waites GM. Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organization Task Force on Methods for the Regulation of Male Fertility. *Fertil Steril.* 1996;65:626–636.

Zmuda JM, Cauley JA, Kriska A, Glynn NW, Gutai JP, Kuller LH. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants. *Am J Epidemiol.* 1997;146:609–617.

Zumoff B, Levin J, Strain GW, et al. Abnormal levels of plasma hormones in men with prostate cancer: evidence toward a two-disease theory. *Prostate.* 1982;3:579–588.